MedTrace Logo

Unlocking New Avenues: Azithromycin Vs Erythromycin in Pre-term, Pre-mature Rupture of Membrane Management

NCT07394725 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2026-02-06

No results posted yet for this study

Summary

This randomized controlled trial at Sahiwal Teaching Hospital (April 2024-March 2025) compared azithromycin and erythromycin for managing preterm premature rupture of membranes (PPROM) in 250 women (28-33+6 weeks gestation). Participants received either azithromycin 500 mg once daily or erythromycin 250 mg every six hours for seven days.

Conditions

  • Pre-term Premature Rupture of Membranes

Interventions

DRUG

Erythromycin

Erythromycin 250 mg orally every 6 hours for 7 consecutive days.

DRUG

Azithromycin

Azithromycin 500 mg orally once daily for 7 consecutive days

Sponsors & Collaborators

  • District Headquarters Teaching Hospital Sahiwal

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-01
Primary Completion
2025-03-31
Completion
2025-03-31

Countries

  • Pakistan

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07394725 on ClinicalTrials.gov